SCHEMBL32661691

SCHEMBL32661691

CCN(c1ncnc2c1ncn2[C@@H]1O[C@H](COS(N)(=O)=O)[C@@H](O)[C@H]1O)C(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LARS1 Q9P2J5 2/20 0.57
▸ TARS1 P26639 2/20 0.56
▸ CA1 P00915 1/20 0.56
▸ CA2 P00918 1/20 0.56
▸ CA4 P22748 1/20 0.56
▸ CA9 Q16790 1/20 0.56
▸ IARS1 P41252 1/20 0.56
▸ RXFP1 Q9HBX9 1/20 0.56
▸ ATG7 O95352 3/20 0.54
▸ ADORA2A P29274 1/20 0.54
▸ ADORA2B P29275 1/20 0.54
▸ UBA6 A0AVT1 1/20 0.53
▸ UBA7 P41226 1/20 0.53
▸ NAE1 Q13564 1/20 0.53
▸ UBA3 Q8TBC4 1/20 0.53
▸ SAE1 Q9UBE0 1/20 0.53
▸ DNPH1 O43598 1/20 0.53
▸ PRKAB2 O43741 1/20 0.53
▸ TRPM2 O94759 1/20 0.53
▸ LDHA P00338 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32661821 0.90 KDM4E (0.63) TARS1CA1CA2CA4CA9
SCHEMBL32661820 0.85 RXFP1 (0.61) CA1CA2CA4CA9RXFP1
SCHEMBL32662391 0.85 RXFP1 (0.60) CA1CA2CA4CA9RXFP1
SCHEMBL32661844 0.85 RXFP1 (0.60) CA1CA2CA4CA9RXFP1
SCHEMBL32662093 0.84 ADORA1 (0.63) LARS1TARS1ATG7UBA6UBA7
SCHEMBL1800042 0.84 ATG7 (0.63) TARS1CA1CA2CA4CA9
SCHEMBL5321913 0.83 ATG7 (0.63) TARS1CA1CA2CA4CA9
SCHEMBL1796966 0.83 ATG7 (0.63) TARS1CA1CA2CA4CA9
SCHEMBL1799778 0.83 LARS1 (0.58) LARS1TARS1CA1CA2CA4
SCHEMBL14201601 0.82 CA1 (0.73) CA1CA2CA4CA9RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015592-A1 NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) 2026-01-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015592-A1 NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF NAE1, NEDD8, UBA3 LARS1 1352/4885TARS1 2153/4885CA1 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback